Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
32.85
+1.76 (5.66%)
Feb 2, 2026, 3:47 PM EST - Market open
Travere Therapeutics Employees
Travere Therapeutics had 385 employees as of December 31, 2024. The number of employees increased by 5 or 1.32% compared to the previous year.
Employees
385
Change (1Y)
5
Growth (1Y)
1.32%
Revenue / Employee
$1,132,016
Profits / Employee
-$229,971
Market Cap
2.94B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 385 | 5 | 1.32% |
| Dec 31, 2023 | 380 | -82 | -17.75% |
| Dec 31, 2022 | 462 | 152 | 49.03% |
| Dec 31, 2021 | 310 | 48 | 18.32% |
| Dec 31, 2020 | 262 | 41 | 18.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Apellis Pharmaceuticals | 710 |
| Arcus Biosciences | 627 |
| Adaptive Biotechnologies | 619 |
| Beam Therapeutics | 510 |
| Tarsus Pharmaceuticals | 323 |
| Dyne Therapeutics | 240 |
| Catalyst Pharmaceuticals | 181 |
| Immunome | 168 |
TVTX News
- 4 days ago - Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think - Seeking Alpha
- 6 days ago - TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses - GlobeNewsWire
- 12 days ago - Top 3 Health Care Stocks That Could Blast Off This Month - Benzinga
- 20 days ago - Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS - Business Wire
- 20 days ago - Travere Therapeutics, Inc. (TVTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 20 days ago - Travere Therapeutics Provides Corporate Update and 2026 Outlook - Business Wire
- 27 days ago - Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 7 weeks ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire